Schulman Associates Institutional Review Board, Inc. announced the acquisition of Florida-based Independent Investigational Review Board, Inc. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, Contract Research Organization (CRO) and clinical research site customers.
"The strengths of the two organizations are remarkably complimentary," said Michael Woods, President and CEO of Schulman. "We are very excited by the added resources and capabilities Independent brings to the combined company."
With offices in Cincinnati, Ohio, and Plantation, Fl., the combined organization will aim to provide the highest level of quality research review services for a very broad range of therapeutic areas and types of human subject research. Separately, each organization is accredited by Association for the Accreditation of Human Research Protection Programs (AAHRPP), and each has a clean recent audit history with Food and Drug Administration. Both organizations, in business more than 20 years, also enjoy strong reputations for performing thoughtful and rigorous reviews while providing the highest level of customer service available.
"Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base," said Kim Lerner, outgoing CEO of Independent.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.